Papillary serous carcinoma of the uterine cervix: A clinicopathologic study of 17 cases

American Journal of Surgical Pathology

Volumn 22, Issue 1, 1998, Pages 113-120

  Zhou, Chen ^a   Gilks, C Blake ^a,b   Hayes, Malcolm ^a   Clement, Philip B ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Adenocarcinoma; Cervix; Papillary serous; Serous

Indexed keywords

CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL EXAMINATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYSTERECTOMY; INFLAMMATORY INFILTRATE; METASTASIS; PAPILLARY CARCINOMA; POSTOPERATIVE CARE; PREOPERATIVE RADIOTHERAPY; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA;

ADULT; AGED; CA-125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYSTADENOCARCINOMA, PAPILLARY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PERIODIC ACID-SCHIFF REACTION; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 0031964425     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-199801000-00015     Document Type: Article

References (25)

1. Atkovar G, Uzel O, Ozsahin M, et al. Postoperative radiotherapy in carcinoma of the cervix: treatment results and prognostic factors. Radiother Oncol 1995;33:198-205.
2. Berek JS, Hacker NF, Fu YS, Sokale JR, Leuchter RC, Lagasse LD. Adenocarcinoma of the uterine cervix: histologic variables associated with lymph node metastasis and survival. Obstet Gynecol 1985;65:46-52.
3. Borras G, Molina R, Xercavins J, Ballesta A, Iglesias J. Tumor antigens CA 19.9, CA 125, and CEA in carcinoma of the uterine cervix. Gynecol Oncol 1995;57:205-511.
4. Costa MJ, McIlnay KR, Trelford J. Cervical carcinoma with glandular differentiation: histological evaluation predicts disease recurrence in clinical stage I or II patients. Hum Pathol 1995;26:829-37.
5. Creasman WT. New gynecologic cancer staging. Gynecol Oncol 1995;58:157-8.
6. Duk JM, De Bruijn HW, Groenier KH, Fleuren GJ, Aalders JG. Adenocarcinoma of the uterine cervix. Prognostic significance of pretreatment serum CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen levels in relation to clinical and histopathologic tumor characteristics. Cancer 1990;65:1830-7.
7. Gilks CB, Clement PB. Papillary serous adenocarcinoma of the uterine cervix: a report of three cases. Mod Pathol 1992;5:426-31.
8. Hanselaar AG, Van Leusen ND, De Wilde PC, Vooijs GP. Clear cell adenocarcinoma of the vagina and cervix: a report of the Central Netherlands Registry with emphasis on early detection and prognosis. Cancer 1991;67:1971-8.
9. Holm R, Skomedal H, Helland A, Kristensen G, Borrensen A, Nesland J. Immunohistochemical analysis of p53 protein overexpression in normal, premalignant, and malignant tissues of the cervix uteri. J Pathol 1993;165:21-6.
10. Inoue M, Fujita M, Enomoto T, et al. Immunohistochemical analysis of p53 in gynecologic tumors. Am J Clin Pathol 1994;102:665-70.
11. Jones MW, Silverberg SG, Kurman RJ. Well-differentiated villoglandular adenocarcinoma of the uterine cervix: a clinicopathologic study of 24 eases. Int J Gynecol Pathol 1993;12:1-7.
12. Kaminski PF, Maier RC. Clear cell adenocarcinoma of the cervix unrelated to dicthylstilbestrol exposure. Obstet Gynecol 1983;62: 720-7.
13. Khalifa MA, Sesterhenn IA. Tumour markers of epithelial ovarian neoplasms. Int J Gynecol Pathol 1990;9:217-30.
14. Leminen A, Paavonen J, Forss M, Wahlstrom T, Vesterinen E. Adenocarcinoma of the uterine cervix. Cancer 1990;65:53-9.
15. McHugh M, Bose S, Palazzo J. p53 expression in endocervical and endometrial adenocarcinomas. Int J Surg Pathol 1995;2:269-74.
16. Moll U, Chalas E, Auguste M, Meaney D, Chumas J. Uterine papillary serous carcinoma evolves via a p53-driven pathway. Hum Pathol 1996;27:1295-300.
17. Rose PG, Reale FR. Serous papillary carcinoma of the cervix. Gynecol Oncol 1993;50:361-4.
18. Saigo PE, Cain JM, Kim WS, Gaynor JJ, Johnson K, Lewis JL Jr. Prognostic factors in adenocarcinoma of the uterine cervix. Cancer 1986;7:1584-93.
19. Shintaku M, Ueda H. Serous papillary adenocarcinoma of the uterine cervix. Histopathology 1993;22:506-7.
20. Tamimi HK, Gown AM, Kim-Deobald J, Figge DC, Greer BE, Cain JM. The utility of immunocytochemistry in invasive adenocarcinoma of the cervix. Am J Obstet Gynecol 1992;166:1655-61.
21. Tashiro H, Isacson C, Levine R, Kurman R, Cho K, Hedrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997;150:177-85.
22. Tseng PC, Sprance HE, Carcangiu ML, Chambers JT, Schwartz PE. CA 125, NB/70K, and lipid-associated sialic acid in monitoring uterine papillary serous carcinoma. Obstet Gynecol 1959;74: 384-7.
23. Young RH, Scully RE. Villoglandular papillary adenocarcinoma of the uterine cervix: a clinicopathologic analysis of 13 cases. Cancer 1989;63:1773-9.
24. Young RH, Scully RE. Invasive adenocarcinoma and related tumours of the uterine cervix. Semin Diagn Pathol 1990;7:205-27.
25. Zhou C, Matisic JP, Clement PB, Hayes M. Cytologic features of papillary serous adenocarcinoma of the uterine cervix. Cancer Cytopathol 1997;81:98-104.